Skip to search formSkip to main contentSkip to account menu

Complete Hematologic Response

Known as: CHR 
The disappearance of cancer in response to treatment, including platelet and white blood cell counts returning to normal levels, a non-palpable… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Abstract 69 Bosutinib (BOS) is an oral, dual Src/Abl kinase inhibitor. In the randomized, phase 3 BELA trial, BOS 500 mg/d… 
2009
2009
Nilotinib restores long-term full-donor chimerism in Ph-positive acute lymphoblastic leukemia relapsed after allogeneic… 
2009
2009
Second-generation tyrosine kinase inhibitors are effective in Philadelphia chromosome-positive (Ph(+)) acute lymphoblastic… 
2009
2009
The most common mechanism of acquired resistance in CML in imatinib era is the acquisition of BCR-ABL kinase domain mutations… 
Review
2007
Review
2007
Recently, increasing the dosage of imatinib mesylate (IM) has been suggested as a method for overcoming IM resistance in CML… 
Highly Cited
2006
Highly Cited
2006
6506 Background: IM was proven to be superior to IFN+Ara-C for newly diagnosed patients (pts) with CML-CP (O' Brien et al, NEJM… 
2005
2005
BACKGROUND In 1986, a Phase II trial of recombinant interferon-alpha (IFN-alpha) was initiated as therapy for patients with… 
Review
2003
Review
2003
Philadelphia-negative acute lymphoblastic leukemia developing in a CML patient in imatinib mesylate-induced complete cytogenetic…